|
1
|
Schulte-Merker S, Sabine A and Petrova TV:
Lymphatic vascular morphogenesis in development, physiology, and
disease. J Cell Biol. 193:607–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alitalo K, Tammela T and Petrova TV:
Lymphangiogenesis in development and human disease. Nature.
438:946–953. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Achen MG, McColl BK and Stacker SA: Focus
on lymphangiogenesis in tumor metastasis. Cancer Cell. 7:121–127.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alitalo A and Detmar M: Interaction of
tumor cells and lymphatic vessels in cancer progression. Oncogene.
31:4499–4508. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stachura J, Wachowska M, Kilarski WW, Güç
E, Golab J and Muchowicz A: The dual role of tumor lymphatic
vessels in dissemination of metastases and immune response
development. Oncoimmunology. 5:e11822782016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shields JD: Lymphatics: At the interface
of immunity, tolerance, and tumor metastasis. Microcirculation.
18:517–531. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mandriota SJ, Jussila L, Jeltsch M,
Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R,
Jackson DG, et al: Vascular endothelial growth factor-C-mediated
lymphangiogenesis promotes tumour metastasis. EMBO J. 20:672–682.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Skobe M, Hawighorst T, Jackson DG, Prevo
R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar
M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast
cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stacker SA, Caesar C, Baldwin ME, Thornton
GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H and Achen
MG: VEGF-D promotes the metastatic spread of tumor cells via the
lymphatics. Nat Med. 7:186–191. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoshida T, Isaka N, Hagendoorn J, di
Tomaso E, Chen YL, Pytowski B, Fukumura D, Padera TP and Jain RK:
Imaging steps of lymphatic metastasis reveals that vascular
endothelial growth factor-C increases metastasis by increasing
delivery of cancer cells to lymph nodes: Therapeutic implications.
Cancer Res. 66:8065–8075. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He Y, Kozaki K, Karpanen T, Koshikawa K,
Yla-Herttuala S, Takahashi T and Alitalo K: Suppression of tumor
lymphangiogenesis and lymph node metastasis by blocking vascular
endothelial growth factor receptor 3 signaling. J Natl Cancer Inst.
94:819–825. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Z, Varney ML, Backora MW, Cowan K,
Solheim JC, Talmadge JE and Singh RK: Down-regulation of vascular
endothelial cell growth factor-C expression using small interfering
RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and
spontaneous metastasis and enhances survival. Cancer Res.
65:9004–9011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Renyi-Vamos F, Tovari J, Fillinger J,
Timar J, Paku S, Kenessey I, Ostoros G, Agocs L, Soltesz I and Dome
B: Lymphangiogenesis correlates with lymph node metastasis,
prognosis, and angiogenic phenotype in human non-small cell lung
cancer. Clin Cancer Res. 11:7344–7353. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyahara M, Tanuma J, Sugihara K and Semba
I: Tumor lymphangiogenesis correlates with lymph node metastasis
and clinicopathologic parameters in oral squamous cell carcinoma.
Cancer. 110:1287–1294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakamura Y, Yasuoka H, Tsujimoto M, Imabun
S, Nakahara M, Nakao K, Nakamura M, Mori I and Kakudo K: Lymph
vessel density correlates with nodal status, VEGF-C expression, and
prognosis in breast cancer. Breast Cancer Res Treat. 91:125–132.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Agarwal B, Saxena R, Morimiya A, Mehrotra
S and Badve S: Lymphangiogenesis does not occur in breast cancer.
Am J Surg Pathol. 29:1449–1455. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Van der Schaft DW, Pauwels P, Hulsmans S,
Zimmermann M, van de Poll-Franse LV and Griffioen AW: Absence of
lymphangiogenesis in ductal breast cancer at the primary tumor
site. Cancer Lett. 254:128–136. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Williams CS, Leek RD, Robson AM, Banerji
S, Prevo R, Harris AL and Jackson DG: Absence of lymphangiogenesis
and intratumoural lymph vessels in human metastatic breast cancer.
J Pathol. 200:195–206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Trojan L, Michel MS, Rensch F, Jackson DG,
Alken P and Grobholz R: Lymph and blood vessel architecture in
benign and malignant prostatic tissue: Lack of lymphangiogenesis in
prostate carcinoma assessed with novel lymphatic marker lymphatic
vessel endothelial hyaluronan receptor (LYVE-1). J Urol.
172:103–107. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koukourakis MI, Giatromanolaki A, Sivridis
E, Simopoulos C, Gatter KC, Harris AL and Jackson DG: LYVE-1
immunohistochemical assessment of lymphangiogenesis in endometrial
and lung cancer. J Clin Pathol. 58:202–206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Steinskog ES, Sagstad SJ, Wagner M,
Karlsen TV, Yang N, Markhus CE, Yndestad S, Wiig H and Eikesdal HP:
Impaired lymphatic function accelerates cancer growth. Oncotarget.
7:45789–45802. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Achen MG and Stacker SA: Molecular control
of lymphatic metastasis. Ann N Y Acad Sci. 1131:225–234. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirakawa S: Regulation of pathological
lymphangiogenesis requires factors distinct from those governing
physiological lymphangiogenesis. J Dermatol Sci. 61:85–93. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng W, Aspelund A and Alitalo K:
Lymphangiogenic factors, mechanisms, and applications. J Clin
Invest. 124:878–887. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshimatsu Y, Miyazaki H and Watabe T:
Roles of signaling and transcriptional networks in pathological
lymphangiogenesis. Adv Drug Deliv Rev. 99:161–171. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sobin LH and Compton CC: TNM seventh
edition: What's new, what's changed: Communication from the
international union against cancer and the American joint committee
on cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Niklinski J, Kretowski A, Moniuszko M,
Reszec J, Michalska-Falkowska A, Niemira M, Ciborowski M,
Charkiewicz R, Jurgilewicz D, Kozlowski M, et al: Systematic
biobanking, novel imaging techniques, and advanced molecular
analysis for precise tumor diagnosis and therapy: The Polish MOBIT
project. Adv Med Sci. 62:405–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Endoh H, Tomida S, Yatabe Y, Konishi H,
Osada H, Tajima K, Kuwano H, Takahashi T and Mitsudomi T:
Prognostic model of pulmonary adenocarcinoma by expression
profiling of eight genes as determined by quantitative real-time
reverse transcriptase polymerase chain reaction. J Clin Oncol.
22:811–819. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Torre LA, Siegel RL and Jemal A: Lung
Cancer Statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Detterbeck FC, Postmus PE and Tanoue LT:
The stage classification of lung cancer: Diagnosis and management
of lung cancer, 3rd ed: American college of chest physicians
evidence-based clinical practice guidelines. Chest. 143 5
Suppl:e191S–e210S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Albrecht I and Christofori G: Molecular
mechanisms of lymphangiogenesis in development and cancer. Int J
Dev Biol. 55:483–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gomes FG, Nedel F, Alves AM, Nör JE and
Tarquinio SB: Tumor angiogenesis and lymphangiogenesis:
Tumor/endothelial crosstalk and cellular/microenvironmental
signaling mechanisms. Life Sci. 92:101–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Regan E, Sibley RC, Cenik BK, Silva A,
Girard L, Minna JD and Dellinger MT: Identification of gene
expression differences between lymphangiogenic and
non-lymphangiogenic non-small cell lung cancer cell lines. PLoS
One. 11:e01509632016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jackson DG: Biology of the lymphatic
marker LYVE-1 and applications in research into lymphatic
trafficking and lymphangiogenesis. APMIS. 112:526–538. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu M, Du Y, Liu Y, He Y, Yang C, Wang W
and Gao F: Low molecular weight hyaluronan induces
lymphangiogenesis through LYVE-1-mediated signaling pathways. PLoS
One. 9:e928572014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu X and Liu NF: FOXC2 transcription
factor: A novel regulator of lymphangiogenesis. Lymphology.
44:35–41. 2011.PubMed/NCBI
|
|
39
|
Pan Y and Xia L: Emerging roles of
podoplanin in vascular development and homeostasis. Front Med.
9:421–430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Baluk P and McDonald DM: Markers for
microscopic imaging of lymphangiogenesis and angiogenesis. Ann N Y
Acad Sci. 1131:1–12. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Elsir T, Smits A, Lindström MS and Nistér
M: Transcription factor PROX1: Its role in development and cancer.
Cancer Metastasis Rev. 31:793–805. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Watabe T: Roles of transcriptional network
during the formation of lymphatic vessels. J Biochem. 152:213–220.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sanmartín E, Sirera R, Usó M, Blasco A,
Gallach S, Figueroa S, Martínez N, Hernando C, Honguero A,
Martorell M, et al: A gene signature combining the tissue
expression of three angiogenic factors is a prognostic marker in
early-stage non-small cell lung cancer. Ann Surg Oncol. 21:612–620.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Takizawa H, Kondo K, Fujino H, Kenzaki K,
Miyoshi T, Sakiyama S and Tangoku A: The balance of VEGF-C and
VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small
cell lung cancer. Br J Cancer. 95:75–79. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Feng Y, Wang W, Hu J, Ma J, Zhang Y and
Zhang J: Expression of VEGF-C and VEGF-D as significant markers for
assessment of lymphangiogenesis and lymph node metastasis in
non-small cell lung cancer. Anat Rec (Hoboken). 293:802–812. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Maekawa S, Iwasaki A, Shirakusa T, Enatsu
S, Kawakami T and Kuroki M and Kuroki M: Correlation between lymph
node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in
T1 lung adenocarcinoma. Anticancer Res. 27:3735–3741.
2007.PubMed/NCBI
|
|
47
|
Li J, Yi H, Liu Z, Zhang H, Zhang D, Yue
W, Jia H, Xu S and Li B: Association between VEGFR-3 expression and
lymph node metastasis in non-small-cell lung cancer. Exp Ther Med.
9:389–394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kilvaer TK, Paulsen EE, Hald SM, Wilsgaard
T, Bremnes RM, Busund LT and Donnem T: Lymphangiogenic markers and
their impact on nodal metastasis and survival in non-small cell
lung cancer-a structured review with meta analysis. PLoS One.
10:e01324812015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zheng CL, Qiu C, Shen MX, Qu X, Zhang TH,
Zhang JH and Du JJ: Prognostic impact of elevation of vascular
endothelial growth factor family expression in patients with
non-small cell lung cancer: An updated meta-analysis. Asian Pac J
Cancer Prev. 16:1881–1895. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang Z, Luo G, Tang H, Cheng C and Wang
P: Prognostic significance of high VEGF-C expression for patients
with breast cancer: An update meta analysis. PLoS One.
11:e01657252016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zong S, Li H, Shi Q, Liu S, Li W and Hou
F: Prognostic significance of VEGF-C immunohistochemical expression
in colorectal cancer: A meta-analysis. Clin Chim Acta. 458:106–114.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xia H, Shen J, Chen S, Huang H, Xu Y and
Ma H: Overexpression of VEGF-C correlates with a poor prognosis in
esophageal cancer patients. Cancer Biomark. 17:165–170. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kato S, Shimoda H, Ji RC and Miura M:
Lymphangiogenesis and expression of specific molecules as lymphatic
endothelial cell markers. Anat Sci Int. 81:71–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jackson DG: Immunological functions of
hyaluronan and its receptors in the lymphatics. Immunol Rev.
230:216–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ugorski M, Dziegiel P and Suchanski J:
Podoplanin-a small glycoprotein with many faces. Am J Cancer Res.
6:370–386. 2016.PubMed/NCBI
|
|
56
|
Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu
SA, Capac CM, Gliksman M, Goy A and Suh KS: Molecular and clinical
significance of fibroblast growth factor 2 (FGF2/bFGF) in
malignancies of solid and hematological cancers for personalized
therapies. Oncotarget. 7:44735–44762. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kowalczyk AP and Green KJ: Structure,
function, and regulation of desmosomes. Prog Mol Biol Transl Sci.
116:95–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Huber O and Petersen I: 150th anniversary
series: Desmosomes and the hallmarks of cancer. Cell Commun Adhes.
22:15–28. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Krisenko MO and Geahlen RL: Calling in
SYK: SYK's dual role as a tumor promoter and tumor suppressor in
cancer. Biochim Biophys Acta. 1853:254–263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bazigou E, Xie S, Chen C, Weston A, Miura
N, Sorokin L, Adams R, Muro AF, Sheppard D and Makinen T:
Integrin-alpha9 is required for fibronectin matrix assembly during
lymphatic valve morphogenesis. Dev Cell. 17:175–186. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rizzolio S and Tamagnone L: Multifaceted
role of neuropilins in cancer. Curr Med Chem. 18:3563–3575. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zachary I: Neuropilins: Role in
signalling, angiogenesis and disease. Chem Immunol Allergy.
99:37–70. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sasahira T, Ueda N, Yamamoto K, Kurihara
M, Matsushima S, Bhawal UK, Kirita T and Kuniyasu H: Prox1 and
FOXC2 act as regulators of lymphangiogenesis and angiogenesis in
oral squamous cell carcinoma. PLoS One. 9:e925342014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Prud'homme GJ and Glinka Y: Neuropilins
are multifunctional coreceptors involved in tumor initiation,
growth, metastasis and immunity. Oncotarget. 3:921–939. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Jiang W, Fan H, Qian C, Ding J, Wang Q and
Pang X: Prognostic value of high FoxC2 expression in resectable
non-small cell lung cancer, alone or in combination with E-cadherin
expression. BMC Cancer. 16:162016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhu JL, Song YX, Wang ZN, Gao P, Wang MX,
Dong YL, Xing CZ and Xu HM: The clinical significance of mesenchyme
forkhead 1 (FoxC2) in gastric carcinoma. Histopathology.
62:1038–1048. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Nishida N, Mimori K, Yokobori T, Sudo T,
Tanaka F, Shibata K, Ishii H, Doki Y and Mori M: FOXC2 is a novel
prognostic factor in human esophageal squamous cell carcinoma. Ann
Surg Oncol. 18:535–542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Skog M, Bono P, Lundin M, Lundin J,
Louhimo J, Linder N, Petrova TV, Andersson LC, Joensuu H, Alitalo K
and Haglund CH: Expression and prognostic value of transcription
factor PROX1 in colorectal cancer. Br J Cancer. 105:1346–1351.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Versmold B, Felsberg J, Mikeska T,
Ehrentraut D, Köhler J, Hampl JA, Röhn G, Niederacher D, Betz B,
Hellmich M, et al: Epigenetic silencing of the candidate tumor
suppressor gene PROX1 in sporadic breast cancer. Int J Cancer.
121:547–554. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Schneider M, Büchler P, Giese N, Giese T,
Wilting J, Büchler MW and Friess H: Role of lymphangiogenesis and
lymphangiogenic factors during pancreatic cancer progression and
lymphatic spread. Int J Oncol. 28:883–890. 2006.PubMed/NCBI
|
|
71
|
Juchniewicz A, Niklińska W, Kowalczuk O,
Laudański W, Sulewska A, Dziegielewski P, Milewski R, Naumnik W,
Kozłowski M and Nikliński J: Prognostic value of vascular
endothelial growth factor-C and podoplanin mRNA expression in
esophageal cancer. Oncol Lett. 10:3668–3674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kadota K, Huang CL, Liu D, Nakashima N,
Yokomise H, Ueno M and Haba R: The clinical significance of the
tumor cell D2-40 immunoreactivity in non-small cell lung cancer.
Lung Cancer. 70:88–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shimada Y, Ishii G, Nagai K, Atsumi N,
Fujii S, Yamada A, Yamane Y, Hishida T, Nishimura M, Yoshida J, et
al: Expression of podoplanin, CD44, and p63 in squamous cell
carcinoma of the lung. Cancer Sci. 100:2054–2059. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ito T, Ishii G, Nagai K, Nagano T, Kojika
M, Murata Y, Atsumi N, Nishiwaki Y, Miyazaki E, Kumamoto T and
Ochiai A: Low podoplanin expression of tumor cells predicts poor
prognosis in pathological stage IB squamous cell carcinoma of the
lung, tissue microarray analysis of 136 patients using 24
antibodies. Lung Cancer. 63:418–424. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ikoma Y, Kijima H, Masuda R, Tanaka M,
Inokuchi S and Iwazaki M: Podoplanin expression is correlated with
the prognosis of lung squamous cell carcinoma. Biomed Res.
36:393–402. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Suzuki H, Onimaru M, Yonemitsu Y, Maehara
Y, Nakamura S and Sueishi K: Podoplanin in cancer cells is
experimentally able to attenuate prolymphangiogenic and
lymphogenous metastatic potentials of lung squamoid cancer cells.
Mol Cancer. 9:2872010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kawakami T, Tokunaga T, Hatanaka H, Kijima
H, Yamazaki H, Abe Y, Osamura Y, Inoue H, Ueyama Y and Nakamura M:
Neuropilin 1 and neuropilin 2 co-expression is significantly
correlated with increased vascularity and poor prognosis in
nonsmall cell lung carcinoma. Cancer. 95:2196–2201. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Donnem T, Al-Saad S, Al-Shibli K,
Delghandi MP, Persson M, Nilsen MN, Busund LT and Bremnes RM:
Inverse prognostic impact of angiogenic marker expression in tumor
cells versus stromal cells in non small cell lung cancer. Clin
Cancer Res. 13:6649–6657. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Donnem T, Al-Shibli K, Al-Saad S,
Delghandi MP, Busund LT and Bremnes RM: VEGF-A and VEGFR-3
correlate with nodal status in operable non-small cell lung cancer:
Inverse correlation between expression in tumor and stromal cells.
Lung Cancer. 63:277–283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Shahneh FZ, Baradaran B, Zamani F and
Aghebati-Maleki L: Tumor angiogenesis and anti-angiogenic
therapies. Hum Antibodies. 22:15–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ferrara N: Role of myeloid cells in
vascular endothelial growth factor-independent tumor angiogenesis.
Curr Opin Hematol. 17:219–224. 2010.PubMed/NCBI
|
|
83
|
Zhao Y and Adjei A: Targeting angiogenesis
in cancer therapy: Moving beyond vascular endothelial growth
factor. Oncologist. 20:660–673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Donnem T, Hu J, Ferguson M, Adighibe O,
Snell C, Harris AL, Gatter KC and Pezzella F: Vessel co-option in
primary human tumors and metastases: An obstacle to effective
anti-angiogenic treatment? Cancer Med. 2:427–436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Bridgeman VL, Vermeulen PB, Foo S, Bilecz
A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T,
et al: Vessel co-option is common in human lung metastases and
mediates resistance to anti-angiogenic therapy in preclinical lung
metastasis models. J Pathol. 241:362–374. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Vieira JM, Ruhrberg C and Schwarz Q: VEGF
receptor signaling in vertebrate development. Organogenesis.
6:97–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang SD, McCrudden CM and Kwok HF:
Prognostic significance of combining VEGFA, FLT1 and KDR mRNA
expression in lung cancer. Oncol Lett. 10:1893–1901. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Pajares MJ, Agorreta J, Larrayoz M, Vesin
A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla
C, et al: Expression of tumor-derived vascular endothelial growth
factor and its receptors is associated with outcome in early
squamous cell carcinoma of the lung. J Clin Oncol. 30:1129–1136.
2012. View Article : Google Scholar : PubMed/NCBI
|
